Onconephrology 2022: An Update

Bonilla, Marco; Gudsoorkar, Prakash; Wanchoo, Rimda; Herrmann, Joerg; Jhaveri, Kenar D.

doi:10.34067/kid.0001582022

Cited by 7 publications

(6 citation statements)

References 120 publications

(231 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Вплив РН загалом і нирково-клітинного раку (НКР) зокрема та методів їх лікування на стан нирок є складним і багатостороннім [2]. НКР нирки може виникнути в інтактній нирці або ж у нирках, які вже уражені (наприклад, ХХН обумовлена різними причинами).…”

Section: Nephrology Schoolunclassified

“…У зв'язку зі значним збільшення у популяції кількості пацієнтів похилого віку з гіпертензією та цукровим діабетом, які у них є як основними при-чинами ХХН (а вона, -незалежний фактор розвитку НКР), так і ризик-факторами злоякісного ураження нирок, вірогідність виникнення НКР суттєво збільшується [2,5].…”

Section: таблиця 3 гломерулярні ураження нирок які викликає нкр [5]unclassified

See 1 more Smart Citation

Onconephrology: Renal cancer

Kolesnyk

2023

Ukr. J. Nephrol. and Dial.

View full text Add to dashboard Cite

Renal cancer (RC) ranks eighth among the most prevalent oncopathologies, making it one of the most widespread types of cancer. Over the last decade, there has been an average annual increase in morbidity of 2 percent. RC is a collective term that encompasses parenchymal tumors and pelvis tumors with distinct histologic characteristics. Renal cancer can appear in intact kidneys and cause additional damage except for the actual tumor process, or in patients with previously affected kidneys. The main treatment option for renal cell carcinoma (RCC) is surgery, which can be performed through various approaches, including open-access surgery, laparoscopic surgery, and robotic-assisted surgery. These surgical techniques enable the performance of radical nephrectomy, partial nephrectomy, and cytoreductive nephrectomy. The selection of the surgical method and the extent of the intervention fall within the expertise of oncourologists. Anti-angiogenic drugs, including tyrosine kinase inhibitors, humanized monoclonal antibodies, and immune checkpoint inhibitors, as well as mTOR inhibitors, are commonly utilized in the treatment of advanced-stage RCC (II-IV) or its relapse. However, it is important to note that these drugs possess considerable nephrotoxicity. Therefore, kidney status plays a crucial role in determining the appropriate treatment options, the dosage of antitumor drugs, and the potential nephrotoxicity associated with them, thereby becoming the main limiting factor affecting the quality and duration of life for RCC patients. The present review focuses on the analysis of recent data concerning the issues mentioned above, primarily in relation to RCC, and provides recommendations for the investigation and treatment of this specific category of patients.

show abstract

Section: Nephrology Schoolunclassified

Section: таблиця 3 гломерулярні ураження нирок які викликає нкр [5]unclassified

Onconephrology: Renal cancer

Kolesnyk

2023

Ukr. J. Nephrol. and Dial.

View full text Add to dashboard Cite

show abstract

“…For example, certain tumors release hormones or other factors that can constrict blood vessels or promote fluid retention, contributing to hypertension; (b) Side effects of cancer treatments; certain cancer treatments, such as chemotherapy agents, targeted therapies, or immunotherapies, can affect blood pressure regulation. For example, some medications may cause fluid retention or damage blood vessels, leading to increased blood pressure; (c) Coexisting conditions; individuals with cancer may have pre-existing conditions like obesity, kidney disease, or cardiovascular diseases, which can contribute to hypertension (2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Onco-hypertension; a collaboration among oncologists, nephrologists and cardiologists

Dehghan¹

2023

J Ren Endocrinol

View full text Add to dashboard Cite

It is essential to manage hypertension in cancer patients because uncontrolled high blood pressure can increase the risk of cardiovascular complications and negatively impact overall health. We searched PubMed, Web of Science, EBSCO, Scopus, Google Scholar, Directory of Open Access Journals (DOAJ), and Embase, using keywords including; hypertension, onco-hypertension, and Neoplasms; and found that several factors can contribute to the development of onco-hypertension, including certain types of cancer, chemotherapy drugs, targeted therapies, and hormonal treatments. Favorable cooperation of multi-specialists in this disease treatment can lead to better and more optimal treatment management for these patients.

show abstract

“…Acute tubulointerstitial nephritis (ATIN) is the most common kidney biopsy-proven finding in ICPI-AKI, resulting in treatment disruption and corticosteroid administration. 11 ICPI-AKI may lead to residual CKD and may recur on ICPI rechallenge. 11 Thus, the pivotal question for nephrologists is whether SGLT2-mediated inhibition of immune checkpoints would lead to ATIN as seen with ICPIs.…”

mentioning

confidence: 99%

“… 11 ICPI-AKI may lead to residual CKD and may recur on ICPI rechallenge. 11 Thus, the pivotal question for nephrologists is whether SGLT2-mediated inhibition of immune checkpoints would lead to ATIN as seen with ICPIs. Despite its widespread use at present, there are only two case reports of ATIN associated with use of SGLT2is for standard indications.…”

mentioning

confidence: 99%